Inoten 20mg 10pcs

Description:

IndicationsThe following painful inflammatory and degenerative musculoskeletal disorders are approved for symptomatic treatment with tenoxicam:One form of arthritis is rheumatoid arthritis.Osteoarthritis.Arthrosis.An example of arthritis is ankylosing spondylitis.extra-articular conditions like tendinitis, bursitis, hip or shoulder periarthritis, as well as strains and sprains.the flare-up of gout.PharmacologyTenoxicam is a nonsteroidal anti-inflammatory drug (NSAID) that can inhibit platelet aggregation and has anti-inflammatory, analgesic, and antipyretic properties. The tenoxicam stops the synthesis of prostaglandins. Leukocyte peroxidase in vitro studies suggests that tenoxicam may act as a scavenger for active oxygen at the site of inflammation. In vitro, tenoxicam prevents the breakdown of cartilage by human metalloproteinases (stromelysin and collagenase). Tenoxicam’s therapeutic success in the management of severe inflammatory and degenerative musculoskeletal diseases is largely attributable to these pharmacological actions. Tenoxicam showed no mutagenic, carcinogenic, or teratogenic effects in animal studies. Similar to other prostaglandin inhibitors, renal and gastrointestinal side effects as well as a higher incidence of dystocia and delayed parturition were noted in animal safety tests.Dosage Standard dosage: A daily dose of 20 mg should be administered at the same time of day for all indications aside from acute gout.Gout attacks that are acute: For gout attacks that are acute, the recommended dosage is 40 mg once daily for two days, followed by 20 mg once daily for an additional five days.Tenoxicam has a therapeutic effect in the early stages of treatment for chronic disorders, but over time, the response gradually improves. Daily doses greater than 20 mg should be avoided in patients with chronic disorders as they would increase the frequency and severity of adverse reactions without appreciably improving treatment outcomes. For patients who require ongoing care should,  a reduction to a daily oral dose of 10 mg may be tried for maintenance.Special dosage instructions: In theory, patients who are elderly or who have kidney or liver disease should still follow the aforementioned dosage advice. There are currently no dosage recommendations for children and adolescents due to a lack of clinical experience.AdministrationTake this medicine in the dose and duration as advised by your doctor.The tablets should be taken with a glass of water. Swallow it as a whole. Do not chew, crush or break it. Inoten is to be taken with food.It is preferable to take this medicine during or immediately after a meal.InteractionSimilar to other NSAIDs, salicylate increases tenoxicam clearance and volume of distribution by displacing it from protein-binding sites. Because there is a higher risk of gastrointestinal side effects when salicylates and other NSAIDs are taken together, this should be avoided. The co-administration of some NSAIDs and methotrexate has been associated with increased plasma methotrexate concentrations, decreased renal tubular secretion of methotrexate, and severe methotrexate toxicity. As a result, when Tenoxicam is used with methotrexate, extreme caution should be observed. In the tiny number of patients who received gold, penicillamine, or probenecid at the same time, no clinically significant interactions were discovered. Because tenoxicam reduces lithium renal clearance, their concurrent treatment may result in elevated plasma levels and lithium toxicity. Lithium levels in the plasma should be constantly checked. Tenoxicam, like other NSAIDs, should not be used in conjunction with potassium-sparing diuretics. These two groups of drugs are known to interact, which can result in hyperkalemia and renal failure. Tenoxicam and furosemide had no clinically significant interactions, but Tenoxicam lessens hydrochlorothiazide’s ability to lower blood pressure. It has been demonstrated that tenoxicam, like other NSAIDs, lessens the antihypertensive effects of ACE inhibitors and alpha-adrenergic blockers. There are no known interactions between NSAIDs and calcium channel blockers or centrally active alpha agonists. Atenolol and tenoxicam did not interact in a clinically significant way. No interactions with digitalis products were noted during clinical studies. As a result, the concomitant dosage of Tenoxicam with digoxin appears to be risk-free. At the prescribed doses, no interactions have been seen with antacids, cimetidine, warfarin, or phenprocoumon. Tenoxicam had no influence on the clinical effect of oral anti-diabetic medicines (glibornuride, glibenclamide, tolbutamide). Nonetheless, when patients are taking anticoagulants or oral diabetes medications at the same time, they should be closely monitored. Tenoxicam and low molecular weight heparin have not been observed to interact clinically.ContraindicationsFor the following reasons, patients shouldn’t receive tenoxicam:known to be hypersensitive to drugs;who suffer from asthma, rhinitis, or urticaria and are sensitive to salicylates or other nonsteroidal anti-inflammatory drugs (NSAIDs);having experienced or currently experiencing an upper gastrointestinal tract condition like gastritis, a gastric or duodenal ulcerSide EffectsBased on clinical trials including large numbers of patients, Tenoxicam proved to be well tolerated in the recommended dose. Usually, the undesirable effects reported were mild and transient. In a small proportion of patients, the interruption of treatment due to undesirable effects was necessary. Local tolerance of Tenoxicam given parenterally was good. The following undesirable effects have been reported:

Frequency is greater than 1%-Gastrointestinal tract: gastric, epigastric, and abdominal discomfort, dyspepsia, heartburn, nausea.Central nervous system: dizziness, headache.Frequency less than 1%-Gastrointestinal tract: constipation, diarrhea, stomatitis, gastritis, vomiting, ulcers, Gl-bleeding including hematemesis and melena.Central nervous system: fatigue, sleep disturbances, appetite loss, dry mouth, vertigo.Skin: itching (also in the anal region after rectal administration), erythema, exanthema, rash, urticaria.Urinary tract and kidneys: increase in BUN or creatinine, edema.Liver and biliary tract: increased liver enzyme activity.Cardiovascular system: palpitations.Isolated cases (frequency less than 0.01%)-Gastrointestinal tract: Gl-perforation.Central nervous system: visual disturbances.Skin: Stevens-Johnson and Lyell’s syndrome, photosensitivity reaction, vasculitis.Blood: anemia, agranulocytosis, leukopenia, thrombocytopenia.Hypersensitivity reactions: dyspnea, asthma, anaphylaxis, angioedema.Cardiovascular system: elevated blood pressure, mainly in patients treated with cardiovascular drugs.Liver/Biliary tract: hepatitis.Pregnancy & LactationNSAIDs decrease prostaglandin production and, when used late in pregnancy, may cause the fetal ductus arteriosus to close, prolong labor, and delay parturition. Treatment should be avoided throughout the third trimester of pregnancy. Tenoxicam enters breast milk at a very tiny level (about 0.2 percent) based on data from single-dose administration. There is no indication of harmful effects in breastfed infants of Tenoxicam-taking mothers. Nonetheless, infants should be weaned or the medication should be stopped.Precautions & WarningsNSAIDs decrease renal prostaglandin production, which may have an adverse influence on renal hemodynamics as well as salt and water balance. When giving Tenoxicam to patients with conditions that could increase their risk of developing renal failure, such as pre-existing renal disease, impaired renal function in diabetics, hepatic cirrhosis, congestive heart failure, volume dilution, etc., it is necessary to adequately monitor the patient with a special emphasis on cardiac and renal function (BUN, creatinine, development of edema, weight gain, etc.).Tenoxicam reduces platelet aggregation and may have an effect on hemostasis. Tenoxicam has no effect on coagulation factors, coagulation time, prothrombin time, or activated thromboplastin time. Patients with coagulation problems or undergoing medication therapy that interferes with hemostasis, on the other hand, should be closely monitored while Tenoxicam is taken. Any Tenoxicam-treated patient who exhibits signs of gastrointestinal illness should be thoroughly watched. Tenoxicam should be discontinued promptly if peptic ulcers or gastrointestinal bleeding develops. If serious skin responses develop (e.g., Lyell’s or Stevens-Johnson syndrome), the therapy should be stopped right away. Tenoxicam has been linked to adverse ocular effects. As a result, the ophthalmic examination is advised for individuals who experience visual problems. Tenoxicam’s strong plasma protein binding necessitates care when plasma albumin levels are significantly decreased. Tenoxicam, like anti-inflammatory medications, may conceal the normal symptoms of infection. Tenoxicam Tablets should not be used by individuals who hate or are unable to tolerate milk products.Storage ConditionsStore at or below 30°C and keep away from light and moisture. Keep out of children’s reach.